Understanding how Galectin-3 affects Graft vs. Host Disease and Graft vs. Tumor responses
Official title: Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) Responses
Funded at Roswell Park Cancer Institute Corp · NIH-10857141 · Data updated 2026-11-12
This study is looking at how a protein called Galectin-3 affects the immune responses in patients who have received a stem cell transplant, with the hope of finding ways to reduce complications like Graft vs. Host Disease and improve recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | June 1, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $249,000 |
| NIH project number | 5R00HL155792-05 |
| Project ID | NIH-10857141 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients undergoing allogeneic hematopoietic cell transplantation for conditions like leukemia, lymphoma, or severe anemia.
✕Less likely to help
Patients who are not undergoing allo-HCT or those with conditions unrelated to GvHD may not benefit from this research.
What this research studies
This research investigates the role of Galectin-3 in regulating Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) responses in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). By studying both murine models and human patients, the research aims to uncover how Galectin-3 influences immune responses and potentially mitigates the severity of GvHD. The approach includes examining the cellular mechanisms of Galectin-3 signaling and its effects on donor and recipient immune cells. This could lead to new therapeutic strategies to improve patient outcomes after transplantation.
Why it matters
Potential benefit: If successful, this research could lead to improved management of Graft vs. Host Disease, enhancing the safety and effectiveness of stem cell transplants for patients.
How similar studies have gone: Previous research has shown promising results in understanding the role of immune regulators like Galectin-3, indicating potential for success in this novel approach.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Mohammadpour, Hemn — Roswell Park Cancer Institute Corp
- Study coordinator: Mohammadpour, Hemn
Related research
Other NIH-funded projects on the same topics.
-
ChronicGVHD: How it happens and new ways to treat it
A large NIH grant is funding research on chronic graft-versus-host disease after stem cell transplant, with a focus on the lungs and other organs, to improve outcomes for patients.
-
Propagation of GVHD through CD4+ T-cell recognition of gut bacteria
Researchers are studying how a patient’s immune cells recognize gut bacteria after stem cell transplant to better understand and manage graft-versus-host disease.
-
How donor DNA affects immune responses in blood stem cell transplants
This study is looking at how changes in donor DNA can help improve the success of stem cell transplants by boosting the body's ability to fight cancer while lowering the chances of complications, and it's aimed at helping patients who are getting these transplants.
-
Understanding and treating chronic graft-versus-host disease and its lung form, bronchiolitis obliterans
This project works to find new treatments that block immune and metabolic drivers of chronic GVHD and bronchiolitis obliterans in people after allogeneic stem cell transplant.
-
How donor DNA affects immune responses in blood stem cell transplants
This study is looking at how changes in DNA from donor cells can affect the immune system during stem cell transplants, with the goal of finding better ways to help patients with serious cancers avoid complications while still fighting the disease.
-
Understanding and treating chronic graft-versus-host disease
This study is looking at how chronic graft-versus-host disease (cGVHD) affects the lungs after a stem cell transplant, and it aims to find new ways to help patients by understanding the immune cells involved in this condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.